Research programme: cyclophilin inhibitors - ContraVir Pharmaceuticals

Drug Profile

Research programme: cyclophilin inhibitors - ContraVir Pharmaceuticals

Alternative Names: 440-02; CPI-431-32; CRV 431; NICAMs - ContraVir

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isotechnika Pharma
  • Developer Aurinia Pharmaceuticals; ContraVir Pharmaceuticals; National Institute of Allergy and Infectious Diseases
  • Class Ciclosporins; Cyclic peptides
  • Mechanism of Action Cyclophilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B
  • Discontinued Coronavirus infections; Hepatitis C; HIV-1 infections; Human papillomavirus infections; Neurological disorders; Reperfusion injury; Viral infections

Most Recent Events

  • 24 Oct 2017 Updated pharmacodynamics data presented at the Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 17 Oct 2017 ContraVir Pharmaceuticals enters into collaboration with the Li Ka Shing Institute of Virology at University of Alberta to evaluate CRV 431 for Hepatitis B treatment
  • 21 Aug 2017 ContraVir has patent protection for cyclophilin inhibitors in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top